Martin Holst Lange, Novo Nordisk’s executive vice president for development, said Novo was “encouraged” by the data. He said only 57% of patients in the trial reached the highest dose.
This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement Friday.
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...
A phase 3 trial of Novo Nordisk’s next-generation obesity ... 25% on calls with investors throughout 2023 and 2024. Martin Holst Lange, executive vice president of development at Novo, repeated ...
we plan to further explore the additional weight loss potential of CagriSema," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. The company stated: "The results ...
Despite falling short of previously announced targets Novo Nordisk is still positive on meeting the primary endpoint of efficacy over placebo. Martin Holst Lange, executive vice president for ...
Martin Holst Lange, executive vice president for development at Novo Nordisk, said in a statement that the company was "encouraged" by the results. He added that with the insights from the trial ...
Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday.View on euronews ...
This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement Friday. The ...